Free tool
FAERS Monitor: Glucagon
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 201849 or its brand name (Glucagon, Glucagon Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
3,600
Serious
2,995
83% of reports
Hospitalization
1,923
Death reported
635
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dyspnoea362
- drug ineffective332
- acute kidney injury323
- hypotension298
- condition aggravated257
- toxicity to various agents237
- haemoptysis224
- anxiety221
- hypoglycaemia207
- pain in extremity207
- asthma196
- off label use193
- nausea186
- vomiting185
- lung disorder184
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 19 |
| 2005 | 24 |
| 2006 | 20 |
| 2007 | 26 |
| 2008 | 23 |
| 2009 | 49 |
| 2010 | 34 |
| 2011 | 53 |
| 2012 | 53 |
| 2013 | 54 |
| 2014 | 83 |
| 2015 | 230 |
| 2016 | 202 |
| 2017 | 210 |
| 2018 | 207 |
| 2019 | 305 |
| 2020 | 353 |
| 2021 | 316 |
| 2022 | 226 |
| 2023 | 303 |
| 2024 | 297 |
| 2025 | 306 |
| 2026 | 207 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,559 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| haemoptysisSignal | 224 | 47.3 | 41.6 | 10,038 |
| hypoglycaemiaSignal | 207 | 25.0 | 21.9 | 4,744 |
| lung disorderSignal | 184 | 22.0 | 19.1 | 3,665 |
| acute kidney injurySignal | 323 | 12.4 | 11.1 | 3,377 |
| asthmaSignal | 196 | 10.1 | 8.9 | 1,613 |
| hypotensionSignal | 298 | 8.7 | 7.8 | 2,037 |
| toxicity to various agentsSignal | 237 | 8.2 | 7.3 | 1,506 |
| condition aggravatedSignal | 257 | 4.9 | 4.4 | 815 |
| anxietySignal | 221 | 4.5 | 4.0 | 614 |
| pain in extremitySignal | 207 | 4.1 | 3.6 | 490 |
| dyspnoeaSignal | 362 | 3.7 | 3.4 | 743 |
| vomitingSignal | 185 | 2.3 | 2.0 | 138 |
| drug ineffective | 332 | 1.5 | 1.3 | 53 |
| nausea | 186 | 1.4 | 1.2 | 19 |
| off label use | 193 | 1.3 | 1.1 | 13 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.